Virginia Retirement Systems ET AL Sells 14,400 Shares of AMAG Pharmaceuticals, Inc. (AMAG)

Virginia Retirement Systems ET AL lessened its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 18.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,000 shares of the specialty pharmaceutical company’s stock after selling 14,400 shares during the quarter. Virginia Retirement Systems ET AL owned approximately 0.18% of AMAG Pharmaceuticals worth $1,181,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in AMAG Pharmaceuticals in the 3rd quarter worth $342,000. Macquarie Group Ltd. purchased a new position in AMAG Pharmaceuticals in the 3rd quarter worth $266,000. 361 Capital LLC purchased a new position in AMAG Pharmaceuticals in the 3rd quarter worth $197,000. Russell Investments Group Ltd. raised its stake in AMAG Pharmaceuticals by 14.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 645,182 shares of the specialty pharmaceutical company’s stock worth $11,903,000 after acquiring an additional 80,217 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its stake in AMAG Pharmaceuticals by 58.8% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock worth $243,000 after acquiring an additional 4,870 shares during the last quarter.

A number of equities analysts have weighed in on AMAG shares. Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, October 23rd. Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Morgan Stanley started coverage on AMAG Pharmaceuticals in a research note on Friday, September 8th. They set an “overweight” rating and a $26.00 price objective for the company. Deutsche Bank reiterated a “hold” rating and set a $24.00 price objective on shares of AMAG Pharmaceuticals in a research note on Thursday, August 31st. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have assigned a buy rating to the company. AMAG Pharmaceuticals has a consensus rating of “Hold” and an average target price of $23.38.

AMAG Pharmaceuticals, Inc. (AMAG) opened at $14.10 on Friday. AMAG Pharmaceuticals, Inc. has a twelve month low of $11.93 and a twelve month high of $36.83. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94.

ILLEGAL ACTIVITY WARNING: “Virginia Retirement Systems ET AL Sells 14,400 Shares of AMAG Pharmaceuticals, Inc. (AMAG)” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/12/08/virginia-retirement-systems-et-al-sells-14400-shares-of-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply